According to a recent consensus report on the management of hyperglycemia in T2D by the American Diabetes Association and European Association for the Study of Diabetes (ADA-EASD) [10], sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and sodium-glucose cotransporter-2 (SGLT2) inhibitors are considered reasonable options for second-line glucose-lowering agents. The gene discussed is DPP4; the disease is Hyperglycemia.